Acquisition by Shallcross Steven A of 25000 shares of Theriva Biologics at 1.043 subject to Rule 16b-3
TOVX Stock | USD 1.28 0.02 1.59% |
Slightly above 51% of Theriva Biologics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Theriva Biologics suggests that some traders are interested. Theriva Biologics' investing sentiment can be driven by a variety of factors including economic data, Theriva Biologics' earnings reports, geopolitical events, and overall market trends.
Theriva |
Filed transaction by Theriva Biologics Director, Officer: Ceo And Cfo. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at thelincolnianonline.com
Theriva Biologics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Theriva Biologics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Theriva Biologics Fundamental Analysis
We analyze Theriva Biologics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Theriva Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Theriva Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
Theriva Biologics is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Theriva Biologics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Theriva Biologics stock to make a market-neutral strategy. Peer analysis of Theriva Biologics could also be used in its relative valuation, which is a method of valuing Theriva Biologics by comparing valuation metrics with similar companies.
Peers
Theriva Biologics Related Equities
XCUR | Exicure | 69.24 | ||||
GOVX | GeoVax Labs | 9.26 | ||||
PTIX | Protagenic Therapeutics | 6.56 | ||||
MRKR | Marker Therapeutics | 5.08 | ||||
AVTX | Avalo Therapeutics | 4.97 | ||||
BDRX | Biodexa Pharmaceticals | 3.86 | ||||
PMVP | Pmv Pharmaceuticals | 2.55 | ||||
PRAX | Praxis Precision | 1.97 | ||||
SABS | SAB Biotherapeutics | 1.95 | ||||
LSTA | Lisata Therapeutics | 1.41 | ||||
REVB | Revelation Biosciences | 1.33 | ||||
VCNX | Vaccinex | 0.56 | ||||
LUMO | Lumos Pharma | 0.46 | ||||
VRPX | Virpax Pharmaceuticals | 3.39 | ||||
SLRX | Salarius Pharmaceuticals | 6.16 |
Additional Tools for Theriva Stock Analysis
When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.